A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit <a rel="external noopener" href="http://pdfs.semanticscholar.org/9339/2cb0ea11689cd6741ef791f71489d58eef95.pdf">the original URL</a>. The file type is <code>application/pdf</code>.
NCI Image-Guided Drug Delivery Summit
<span title="2011-01-11">2011</span>
<i title="American Association for Cancer Research (AACR)">
<a target="_blank" rel="noopener" href="https://fatcat.wiki/container/czhppgb4znaghaxcyto6oc7jhe" style="color: black;">Cancer Research</a>
</i>
Preserved Fulltext
On April 17, 2010, scientists from academia, the National Cancer Institute (NCI), and the Food and Drug Administration (FDA) assembled at "The NCI Image Guided Drug Delivery Summit," in Washington D.C., to discuss recent advances, barriers, opportunities, and regulatory issues related to the field. The meeting included a scientific session and an NCI/FDA session, followed by a panel discussion of speakers from both sessions. Image-guided drug delivery (IGDD) in cancer is a form of
<span class="external-identifiers">
<a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.1158/0008-5472.can-10-2629">doi:10.1158/0008-5472.can-10-2629</a>
<a target="_blank" rel="external noopener" href="https://www.ncbi.nlm.nih.gov/pubmed/21224356">pmid:21224356</a>
<a target="_blank" rel="external noopener" href="https://pubmed.ncbi.nlm.nih.gov/PMC3075539/">pmcid:PMC3075539</a>
<a target="_blank" rel="external noopener" href="https://fatcat.wiki/release/ssudweu7p5blfhqvzefong6zri">fatcat:ssudweu7p5blfhqvzefong6zri</a>
</span>
more »
... therapy where imaging methods are used in guidance and monitoring of localized and targeted delivery of therapeutics to the tumor. So, a systematic approach to IGDD requires mechanisms for targeting, delivery, activation, and monitoring of the process. Although the goal in IGDD is to optimize the therapeutic ratio through personalized image-guided treatments, a major challenge is in overcoming the biological barriers to the delivery of therapeutics into tumors and cells. Speakers discussed potential challenges to clinical translation of nano-based drug delivery systems including in vivo characterization of nanocarriers, preclinical validation of targeting and delivery, studies of biodistribution, pharmacokinetics, pharmacodynamics, and toxicity as well as scale-up manufacturing of delivery systems. Physiologic and quantitative imaging techniques may serve as enabling tools that could potentially transform many existing challenges into opportunities for advancement of the field. Cancer Res; 71(2); 314-7. Ó2011 AACR.
<a target="_blank" rel="noopener" href="https://web.archive.org/web/20190301230941/http://pdfs.semanticscholar.org/9339/2cb0ea11689cd6741ef791f71489d58eef95.pdf" title="fulltext PDF download" data-goatcounter-click="serp-fulltext" data-goatcounter-title="serp-fulltext">
<button class="ui simple right pointing dropdown compact black labeled icon button serp-button">
<i class="icon ia-icon"></i>
Web Archive
[PDF]
<div class="menu fulltext-thumbnail">
<img src="https://blobs.fatcat.wiki/thumbnail/pdf/93/39/93392cb0ea11689cd6741ef791f71489d58eef95.180px.jpg" alt="fulltext thumbnail" loading="lazy">
</div>
</button>
</a>
<a target="_blank" rel="external noopener noreferrer" href="https://doi.org/10.1158/0008-5472.can-10-2629">
<button class="ui left aligned compact blue labeled icon button serp-button">
<i class="external alternate icon"></i>
Publisher / doi.org
</button>
</a>
<a target="_blank" rel="external noopener" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3075539" title="pubmed link">
<button class="ui compact blue labeled icon button serp-button">
<i class="file alternate outline icon"></i>
pubmed.gov
</button>
</a>